chevron_leftBack
As of 10 June 2026, OliX Pharmaceuticals, Inc. has a market cap of $2.46B USD, ranking #6167 globally and #148 in South Korea.
It ranks #489 in the Healthcare sector, and #190 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$2.46BUSD
3.75T KRW
Enterprise Value
$2.38BUSD
3.64T KRW
Revenue (TTM)
$9.61MUSD
14.67B KRW
EBITDA (TTM)
-$18.03MUSD
-27.52B KRW
Net Income (TTM)
-$10.31MUSD
-15.74B KRW
EBITDA Margin
-188%
Profit Margin
-107%
PS Ratio
255.5
PB Ratio
25.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dong-Ki Lee
open_in_new
Founded
2010
Website
olixpharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.6% | 11% | -7.9% | 23% | 76% | 287% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
226950
올릭스 주식회사 Ordinary Shares
ISIN: KR7226950004
Shares Out.:
Shares Outstanding:
20.301M1
Shares Float:
16.33M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
172,500 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About OliX Pharmaceuticals, Inc.
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.11B
271%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.75B
175%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.22B
113%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.95B
101%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.53B
85%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.43B
80%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
31K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
22K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
15K%
|
97.4
|
|
SIX: RO
|
$321.16B
13K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.62B
12K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.35B
11K%
218.9B CHF
|
20.5
|
chevron_leftBack